Mikhail Blagosklonny and His Bets on Rapamycin as an Anti-aging Drug

Mikhail Blagosklonny, a leading researcher in anti-aging and oncology, has bigger bets on Rapamycin as an anti-aging drug. He says that no death is without reason and most people die due to age-related diseases. Blagosklonny addresses age-related diseases, such as hypertension, atherosclerosis, Alzheimer, Parkinson disease, diabetes, and more, as bio-makers of aging. He points out that many of those are not considered as diseases as it is generally observed in people in the later ages. Blagosklonny further says that organismal aging is linked to cellular aging, a mechanistic or mammalian target of rapamycin or mTOR-dependent process. It is identified that the mTOR pathway is promoted by some growth factors such as nutrients, hormones, oxygen, and more information click here.

Blagosklonny states that mTOR activates various functions of cells that result in cellular mass growth. He identifies that mTOR causes cellular hyperfunctions and hypertrophy. Apart from the final stages of age-related diseases, the process of aging is often connected with systemic hyperfunctions such as increased platelet aggregation, increased blood pressure, hyper coagulation, hyperlipidemia, hyperinsulinemia, hyperglycemia, increased resistance to hormones, and more. It is confirmed that these hyperfunctions are making the organs damaged. Blagosklonny says that aging is a normal working process of cells and organs that are observed during the young ages.

Through his research, Blagosklonny has identified that Rapamycin can significantly reduce these hyperfunctions that cause aging at a later point in their life. He says that the drug has the ability to suppress geroconversion – the cellular basis of aging. It also goes for calorie restrictions that restrict mTOR and improve lifespan. Rapamycin is also considered as an excellent choice of drug for many age-related diseases as well. Finally, Blagosklonny also confirmed that Rapamycin could extend lifespan in all the species it was tested. Blagosklonny also identified that the drug delay cancer by slowing the aging process, and this factor makes Rapamycin as an excellent choice for cancer treatments and learn more about Mikhail.

Mikhail Blagosklonny is also a philanthropist and professor, and he is on a mission to ensure best treatment options available to every patient irrespective of their financial standing. Apart from being a researcher, he is also a mentor to aspiring researchers and his colleagues. Researchers across the world consult with him to get inputs and feedbacks on their research. By researching in oncology, Blagosklonny dreams to develop treatment procedures that are more effective and less expensive than current times. He is working on ways to remove cancerous cells from the human body without causing any damage to the healthy cells. It is identified that not harming healthy cells is important in the recovery of both body and mind after the treatment and resume him.

Blagosklonny has worked with a number of research institutes such as Roswell Park Cancer Institute, Ordway Research Institute, and more. He started his career with New York Medical College as an associate professor, immediately after completing his education. Blagosklonny has written at least 300 research papers, articles, medical reviews, and more. He also collaborated with a number of medical journals. Blagosklonny completed his M.D. and Ph.D. from the First Pavlov State Medical University and Mikhail’s lacrosse camp.

The Budding Career of Dr. Jennifer Walden in the Field of Plastic Surgery

About Dr. Jennifer Walden

Dr. Jennifer is a plastic surgeon, academic, and media commentator. Born in Texas, Dr. Walden acquired her degree in Biology from the University of Texas. She then joined the University of Texas Medical Branch where she graduated as salutatorian. She began her career while still at the Texas Medical Branch and learn more about Dr. Walden.

 

Career

Dr. Jennifer Walden first work was at the Manhattan Eye, Ear and Throat Hospital. While she was working at the hospital, Dr. Walden was mentored by Dr. Sherrell Aston. She later went on to work on the Upper East Side of New York where she was involved in clinical trials. She also spearheaded the reintroduction of Silicone breast implants.

Her extensive experience in New York gave her confidence to start her own practice known as Jennifer L. Walden Reviews, M.D., PLLC in Texas. Throughout her career, Dr. Walden has received a lot of recognition in her field. In 2014, she was listed as one of the Harper’s Bazaar’s 24 Best Beauty Surgeons. As a plastic surgeon, she has opted for the use of advanced technology which helps her work more efficiently. Her use of Vectra, a 3-D imaging technology, has made her a popular surgeon among many and more information click here.

 

Jennifer L. Walden, M.D., PLLC

Through her practice, Dr. Walden has been able to touch the lives of many people who come seeking her services. She specializes in facial surgery, aesthetic breasts, and breast augmentation. Her excellence in her field of work has made her a much sought after plastic surgeon both locally and internationally.

She seeks to help people achieve the best look they can possibly acquire. Dr. Jennifer Walden also consults for the aesthetic companies and has written several journals on the topic of plastic surgery. She is definitely a woman who has a great passion for her work and Dr. Walden’s lacrosse camp.

Securus Technology-The Best Prison Technology Provider

Securus technology is one of the greatest penitentiary technology suppliers. Securus Company serves over 1000000 inmates. The company also works with the government in securing their database to prevent it from landing in unauthorized hands. The company has an excellent reputation in its area of specialization from its network providers.

One of the most major developments of the Secures technology is connecting the prisoners to their family through means of communication. The company has provided mobile phones to the prisons where the prisoners can keep in touch with their families. This is a significant development because the detainees have access to both the video calls and voice calls at their disposal.

Such technology may seem risky in the hands of prisoners. It may be a significant risk to the outside world. However, Securus Technologies is concerned with the security of both the detainees and the outside world. The company has, therefore, taken measures on ensuring this technology is only used for the purpose it was built for exclusively. All the calls are recorded and could be used as evidence in the case of any problem. The calls are strictly monitored by the system to make sure they do not endanger the citizens.

The Securus technology gadgets have been used in many investigative units to solve many mystery cases. This is possible because their technology is highly coded and can only be cracked by the service providers, making it very secure and reliable.

Securus Technologies is an innovative company that protects both the citizens and inmates. The company offers the prison facilities with gadgets that are highly protected from any risks of causing trouble. This precaution is to ensure their no cases of prison breaks or the people outside prison being hurt with the collaboration of the detainees through the communication system. Securus has, therefore, succeeded in improving the lives of the inmates as well as protecting the citizens.

 

Doe Deere Provides Passion And Inspiration For Individuals Interested In Beginning A Business

Doe Deere has taken her passion for cosmetics and turned it into a successful business called Lime Crime. Her line includes lipsticks, eye shadows, nail polish, and so much more. She started her business in 2004 and any individual interested in founding a business of their own can learn a lot from Doe Deere. The combination of her passion and her unique business ideas has made her both successful and popular.

 

According to Doe Deere you start by forming a business plan based on your passions. She cautions you must have everything you require in addition to a workable business plan before you actually begin your business. This establishes an order and helps when you apply for financial assistance. Any company who issues loans including banks use your business plan to ascertain if your business is worth their investment. The best format is to write down your ideas and separate the different components into sections.

 

There are numerous considerations involved in beginning a business. Doe Deere understands the concept takes determination, time, and money. You must realize in the beginning you will be working substantial hours for minimal pay. If you can’t accept this you are not ready to have your own business. When all your determination and hard work start to pay off your business becomes quite rewarding. You develop confidence in the services and goods you offer and start understanding about startups, financial assistance, and market trends. This is how you achieve a successful business. Doe Deere is responsible for the inspiration individuals have found in beginning a business. She strongly believes the time you spend writing down ideas and thoughts and doing research are critical in forming a business.

 

Doe Deere registered a new eBay account in 2004 called Lime Crime for her new fashion line. At the time she was doing all her own modeling and wanted a specific look. She wanted her staple to be colorful cosmetics and her brand was formed partly out of necessity and partly from inspiration. Lime Crime was launched in 2008 because the colors she imagined were almost impossible to find.

 

Doe Deere established her biggest success when she created a new category. This was a lipstick that went from liquid to matte and does not crumble, stays on, and is transfer-proof. She spent months working with a chemist in the lab until she had the perfect formula. Her line is vegan with nothing derived from animals.

Visit http://www.doedeere.com/ to learn more.

Become A Wine Consultant For The Traveling Vineyard

The Traveling Vineyard has become one of the most profitable ways for people to earn extra income when they are working from home. Many stay-at-home moms do not have the opportunity to work a typical job where they are getting out to work on a daily basis. In these situations it is so much easier for these mothers to find an occupation where they can work their own hours and set their own schedule.

The Traveling Vineyard provides a way for wine consultants to sell wine and have wine tasting parties. This is how they are able to move the products that they are selling. When someone decides to have a wine hosting party they get a chance to taste wine, but they also get a chance to get wine pairing advice from the consultants. This is something that allows people to see what wines are going to go best with certain food.

There’s definitely a lot of buzz about the Traveling Vineyard because it provides people with access to exclusive wines that cannot be found anywhere else. People that are looking for a side gigs or a full-time positions as a consultant will find that this is a very profitable industry to engage in.

The thing that many people like about this consultant position is that it does not require a lot of money to start up this business. Many people that engage in small business opportunities will find themselves losing a fortune just in the process of starting the business up. Wit the Traveling Vineyard people can start their businesses at a very reasonable start up cost and get all of the information that they need to handle their business as a consultant. There is even a website called The Tasting Room that allows new wine consultants to become familiar with what the Traveling Vineyard sales. This is a great opportunity for any one that may have considered the possibility of becoming a consultant that gives information on wine. People that sign up to become consultants have no limitations on the amount of money that they can make.

For more information about Traveling Vineyard, just click here.

Amicus Therapeutics Developing Medication for Rare Ailments

According to reports published on PhillyPurge.com, FDA allowed Amicus Therapeutics to submit the New Drug Application (NDA) for migalastat. This decision was reached after U.S. FDA and Amicus Therapeutics concluded a series of discussions that gave the latter the leeway to proceed with its NDA for migalastat submission. The New Drug Application is an oral medication for Fabry sickness and was prepared through Subpart H. This was a strategy to accelerate the NDA’s approval process by providing existing data like previous clinical research, and also showing a reduction in the disease-causing substrate (GL-3). Continuous accumulation of the ailment-causing substrate such as kidney failure, stroke, heart disease and pain is the major cause of mortality rate in Fabry disease.

 

According to Amicus Therapeutics’ Chief Executive Officer and chairman, John F. Crowley, the FDA’s guidance played a significant role of assisting patients living with Fabry complications in the U.S. Furthermore, he said it was a great honor for all those involved in developing migalastat because of what they have achieved so far (https://yourbeautycraze.com/amicus-therapeutics-introduces-galafold-fabry-disease-patients/). The Amicus Therapeutics’ CMO, Jay Barth, said they had provided clinical test data to support migalastat’s approval in Switzerland, Israel, and EU, as well as the ongoing regulatory submissions in Canada, Australian, and Japan.

 

Clinical Data Provided by Amicus Therapeutics

 

Amicus Therapeutics performed two major clinical studies to support the drug’s medicinal value on Fabry Disease. According to Jay Berth, the willingness expressed by U.S. FDA to review their migalastat data is a proof that the company’s data is clinically and scientifically based. He expressed optimism that the recent migalastat submissions were evident it would be approved soon.

 

About Amicus Therapeutics

 

Amicus Therapeutics is a biopharmaceutical firm with global operations. It was established in 2002 and became a public entity in 2007 using trading symbol FOLD, which is under NASDAQ (Google Finance). It specializes in developing therapies to assist patients with rare diseases. Some of these rare sicknesses include Fabry, Pompe disease, Epidermolysis Bullosa and genetically connected skin disorder. The firm is headquartered in Cranbury, NJ. Amicus Therapeutics has developed numerous products including migalastat and SD-101, which are in their last stages of development. The company’s objective is to ensure patients with rare diseases have a hope of living longer.

 

Jason Halpern Is An Innovative Real Estate Developer and Philanthropist

Jason Halpern is best known for his involvement in the development of real estate. He is the creator of JMH Development and has been the force behind his company since 2010. He has been responsible for the completion of land assemblages in numerous locations including New York City, Southern California, Miami Beach, and Las Vegas. Jason Halpern represents the third generation in the field of real estate development and with a track record of impressive proportions. He has spent nearly a half of a century in the construction and management of a wide variety of New York properties. JMH Development currently has $500 million in capital invested in these projects including a luxurious apartment complex and high end townhouses in Brooklyn. Jason Halpern is admired and respected for his unwavering commitment to providing building known for their creativity and innovation. He works primarily in New York state and offers rental properties and spaces for commercial businesses.

Jason Halpern: Born to Develop Property

The Halpern family has established an excellent reputation in New York due to the projects they have completed. They have constructed hundreds of beautiful apartments for the residents of Westchester County, New York, and are responsible for the development of several million square feet of commercial property in the same area. Jason Halpern has property development in his blood and has added his own unique flair, expertise, skill, and vision. His foresight and leadership was responsible for JMH Development leading the way in acquiring numerous high end properties including numerous historical landmarks. He has helped make his company a pioneer in their field.

Jason Halpern: Real Estate Entrepreneur

Jason Halpern additionally combined his passion for philanthropy with his business resulting the participation of JMH Development in numerous charitable initiatives. In 2015 a successful partnership began between JMH Development and a non-profit global water charity. Every contract that receives a signature at the Three Hundred Collins development in Miami results in the funding of water projects in Nepal and Ethiopia. JMH is working with two charities, Splash and Relief Society of Tigray to provide water that is safe and clean to an excess of 650 locals in Nepal and Ethiopia.

A Look At The Profile Of Amicus Therapeutics

Amicus Therapeutics is a renowned biopharmaceutical company based in New Jersey. The company went public in 2007. It was financed by various venture capital firms, including Canaan Partners, New Enterprise Associates and Radius Ventures. Amicus Therapeutics deals with rare and orphan diseases, primarily lysosomal storage disorders. They develop enzyme replacement therapies (ERRs) on the platform of Chaperon- Advanced Replacement Therapy (CHART). In 2014, Amicus Therapeutics stood out in the pharmaceutical industry when it was named “Broadest Portfolio of small molecules pharmacological chaperones.” The company’s first drug candidate is migalastat, a therapy used to stabilize endogenous mutant alpha-galactosidase in Fabry disease. Amicus Therapeutics also entered a three-year partnership with JCR Pharmaceutical and GlaxoSmithKline in the clinical trials of the co-formulation with recombinant alpha-galactosidase.

In 2008, Amicus Therapeutics expanded its operations to San Diego where they built a new research site. Michael J. Fox Foundation funded their research at UCLA, which was collaborated by David Geffen School of Medicine, with $500,000. Their pre-clinical partnership with Icahn School of Medicine in Mount Sinai also received $210,300 from the Alzheimer’s Drug Discovery Foundation in 2012 (https://finance.yahoo.com/quote/FOLD?ltr=1). The company acquired Callidus Biopharma in 2013, which helped them to expand their enzyme replacement therapy development for the treatment of Pompe disease. This was followed by the acquisition of Scioderm in 2015.

The company’s stable presence in the industry has been driven by its visionary leadership. John F. Crowley serves as CEO and chairman of the board. John’s transformative leadership is driven by his desire to deliver solutions to the orphan disease community (GoogleFinance). His mission is inspired by a first-hand experience where two of his children were diagnosed with Pompe disease in 1998. John holds a BS in Foreign Service and an MBA from the George Washington University and Harvard University respectively. He also holds a J.D from the University of Notre Dame Law School. Bradley L. Campbell is the president and COO of Amicus Therapeutics. He has over 15 years of experience in the orphan drug. Bradley has worked for top companies in the industry. He is a graduate of Duke University and Harvard University where he attained his B.A in Public Policy and earned his MBA respectively.

The Role of the Osteo Relief Institute in Management of Osteoarthritis

Arthritis is a common disorder that affects the joints. It develops as people age and mostly occurs among women. There are different forms of arthritis and osteoarthritis is the most common one. An individual with this particular condition will experience degeneration of the soft tissue found between the joints. Since cartilage is broken down, only bone is left. The friction that takes place when the bones rub against each other causes pain. This will lead to swelling and stiffness around the area. Eventually, the pain becomes chronic and unbearable for any individual. There are different factors that put individuals at risk for osteoarthritis. Some include previous injury and having excessive weight. Those with a family history of this condition are also at risk.

There is no known cure for this ailment but there are different ways to manage the pain. This involves exercise and specific medical treatments. Physical activity may hurt for those with arthritis. However, it helps prevent loss of mobility in the affected region. Too much stress on the joints should be avoided as it leads to more pain. Due to this, gentle exercises should be selected. These include stretching and gradual training to increase the strength of the joints. Physical therapy is among the common options used during treatment. It is often an alternative to surgery if an individual stays committed to the treatment. Therapy teaches the patients how to move and minimize the pain that they experience. Surgery is not an option that should be ruled out. However, patients need to be aware of the pros and cons of going for this option.

 

The Osteo relief institute is a facility based in New Jersey that caters to patients with osteoarthritis. It aims to relieve patients of the pain they have to endure and if not so, just lessen the amount of pain they feel. The Osteo relief institute invests in the most advanced treatments to ensure this. Experts in the institute stay up to date with any technological changes that occur and may be instrumental during the treatment processes for patients in the Osteo relief institute. The equipment functions to identify where the pain is from through screening and provide accurate treatment for the individual.

More about Osteo Relief Institute Facebook | Manta | LinkedIn

Tony Petrello; Highest Paid Ceo in 2013, America

Anthony G. Petrello is the current president, CEO and chairman of the board of directors of Nabors Industries Ltd. Anthony G. Petrello is a businessman who owns Nabors Industries which was founded as Anglo Energy Ltd in 1968. The company is based in Hamilton, Bermuda. It is an oil, gas and geothermal drilling company operating in the Americas, Africa, The Far East and The Middle East. It also facilitates on shore drilling services in North America. Mr. Petrello holds a Degree from Harvard Law School and Mathematics Degrees from Yale University and more information click here.

Compensation

Tony Petrello made a total compensation of $15,202, 689 for the fiscal year of 2016. A total of $1,575,000 was received as a salary and learn more about Anthony.

News Feed From Room Mate: Lloyd Grove

Lloyd Grove could not believe his eyes when he was browsing through the internet one day and found out that his once-18-year-old friend, whom he shared a room with in college, was listed as the highest paid CEO. Grove narrates that Petrello was an American- Italian with a thick Jersey accent who would like joking a lot including his family’s supposed connection to the mob. Grove says that Petrello was a mathematical genius who would sometimes scribble theorems on greasy napkins. Petrello was so bright that he was supposed to follow in the footsteps of a world famous mathematician called Prof. Serge Lang. Lang- says Grove- who died in 2005 would have been so disappointed to hear that Petrello opted to study law instead of becoming his protégé and his Twitter.

Family Background

Tony Petrello married his college girlfriend, Cynthia Carrafa. She was a soap opera actress and producer and together they started a family. When their daughter Carena was born prematurely and with complications, they donated $7 million for research at the neurological research facility at Texas Children’s hospital.

More Visit: http://www.bloomberg.com/research/stocks/private/person.asp?personId=290691&privcapId=290681